BFEC
RARE icon

Benjamin F. Edwards & Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Benjamin F. Edwards & Company’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$4K Buy
90
+56
+165% +$2.39K ﹤0.01% 1955
2024
Q1 		$2K Buy
+34
New +$1.6K ﹤0.01% 2038
2022
Q2 		– Sell
-46
Closed -$3K – 1882
2022
Q1 		$3K Sell
46
-688
-94% -$47.9K ﹤0.01% 1622
2021
Q4 		$62K Hold
734
– – ﹤0.01% 995
2021
Q3 		$66K Buy
+734
New +$66.3K ﹤0.01% 960

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Benjamin F. Edwards & Company's RARE Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Ultragenyx Pharmaceutical (RARE) stake by 165% in Q2 2024, buying an estimated $2.39K and bringing the position to 90 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Benjamin F. Edwards & Company first reported a position in RARE in Q3 2021 and has held it in 5 quarters since. The position peaked at $66K in Q3 2021. 275 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

  • Benjamin F. Edwards & Company held 90 shares of Ultragenyx Pharmaceutical worth $4K as of Q2 2024.
  • Benjamin F. Edwards & Company bought 56 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $2.39K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1955 holding.
  • Benjamin F. Edwards & Company first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and has held it in 5 quarters since.
  • Benjamin F. Edwards & Company's Ultragenyx Pharmaceutical position peaked at $66K in Q3 2021.
  • 275 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.